Table 2.

HI antibody response

Seroprotection rate prevaccinationHealthy controlsNontreated mRCC controlsSunitinib-treated patientsSorafenib-treated patientsPa
n = 11n = 7n = 16n = 6
Frequency(%)Frequency(%)Frequency(%)Frequency(%)
 H3N2191144253500.255
 H1N14363428503500.904
 B65557111694670.859
 Protected (all 3 viruses)191142132330.580
Seroprotection rate postvaccination
 H3N276468613814670.628
 H1N198257114884670.666
 B111006861610061000.184
 Protected (all 3 viruses)65534212753500.604
Seroresponse rate postvaccination
 H3N22184574251170.265
 H1N14361144251170.704
 B4362295312330.987

Note: HI antibody response upon vaccination. Values at baseline (before vaccination) and on day 22 after vaccination. Seroprotection was defined as an antibody titer of 40 or more. Subjects were considered fully protected if they had protective titers to all 3 viral strains, partially protected when having protected titers only to 1 or 2 virus types, and nonprotected when titers were less than 40. Postvaccination seroresponses were defined as a significant (≥ 4-fold) increase in titer. The results were compared between the groups with the χ2 test (a).